Market Overview

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm


Schall Law Firm
, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Recro Pharma,
Inc. ("Recro Pharma" or "the Company") (NASDAQ: REPH)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Exchange Commission.

Investors who purchased the Company's shares between July 31, 2017, and
May 23, 2018, inclusive (the ''Class Period''), are encouraged to
contact the firm before July 30, 2018.

If you are a shareholder who suffered a loss, click
here to participate

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm's website at,
or by email at

The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.

According to the Complaint, Recro Pharma made false and misleading
statements to the marketplace. The Company's lead product, IV meloxicam,
was unlikely to receive FDA approval due to lacking sufficient
supporting clinical data to demonstrate significant clinical benefits.
As a result, Recro Pharma's public statements were materially false and
misleading throughout the class period and did not accurately reflect
the results of business operations and the financial health of the
Company. According to the lawsuit, when accurate information about the
Company became apparent in the market, investors suffered damages.

the case
to recover your losses.

The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.

View Comments and Join the Discussion!